Professor Yu's article takes access to medicine in developing countries as its central example to describe how U.S./E.U./W.T.O. treaty requirements—specifically, that developing countries adopt a westernized/modern IP law regime—restricts those countries in their responses to internal health emergencies. The piece suggests that countries should be given policy space to adopt things like compulsory licenses that would keep the prices of drugs down while still respecting multinational pharmaceutical companies' intellectual property rights. The author is a leading scholar in International IP law, and is currently writing a casebook based on the same research that led to this Article.